Join to view full profile
460 W 12th AveColumbus, OH 43210
Phone+1 614-366-0172
Dr. Li is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a cancer immunologist and medical oncologist with passion in discovering and translating knowledge to improve care of patients with cancer.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1997 - 1999
Montefiore Medical CenterResidency, 1994 - 1997
Henan Medicine UniversityClass of 1984
Certifications & Licensure
OH State Medical License 2019 - 2028
SC State Medical License 2010 - 2019
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Elected member of ASCI, AAP and AAAS
Publications & Presentations
PubMed
- Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.Sumithira Vasu, Nathan Denlinger, No-Joon Song, Danielle Elsberry, Qiuhong Zhao
Blood Cancer Discovery. 2026-07-14 - RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma.Bettina Nadorp, Audrey Lasry, Sanam Loghavi, Ravi Patel, Hager Mansour
Blood Cancer Discovery. 2026-05-20 - ZFP148 is a transcriptional repressor of cytolytic effector CD8T cell differentiation.Tong Xiao, Xingyu Chen, No-Joon Song, Ryan J Brown, Anjun Ma
Nature Immunology. 2026-04-01
Press Mentions
The Surprising COVID Vaccine Side Effect No One's Talking AboutNovember 10th, 2025- 10 Must-Read Posts in Immuno-Oncology This WeekOctober 6th, 2025
- ‘Proteotoxic Shock’: Ohio State Researchers Uncover Hidden Mechanism Behind Immunotherapy FailureOctober 5th, 2025
Grant Support
- Targeting GARP-TGFbeta for Immunotherapy of Non-Small Cell Lung CancerOHIO STATE UNIVERSITY2024–2029
- Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial MetabolismOHIO STATE UNIVERSITY2021–2026
- Targeting GRP94-TGF-beta Pathway for Cancer ImmunotherapyOHIO STATE UNIVERSITY2021–2026
- Overcoming hypoxic resistance to anti-cancer therapyOHIO STATE UNIVERSITY2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
